Brazil is Latin America’s largest player, known for having a uniquely protected economy and distinctive language which sometimes makes it a difficult market to understand. In the past few years, the local cannabis regulations have moved from individual patient imports for compassionate use to a recent series of reforms issued by the Brazilian Health Regulatory Agency, ANVISA, allowing for certain exceptions to the general prohibition of cultivating cannabis.
After patients had access to the medical benefits of cannabis, they have continued to demand more and, with a population of over 210 million people and cannabis imports growing up to 60% as of March 2026, the country has a unique opportunity in its hands. Local production regulations are right around the corner, and with demand already existing inhouse, the potential is undeniable.
Thankfully, other countries in the region have prior experience to offer their Portuguese-speaking neighbor. Colombia, a promise that has not yet fulfilled and has been regulating medical cannabis for the past ten years, can offer some valuable insight in this time when all eyes are on Brazilian imports.
Lesson #1: Slow and Steady Wins the Race
Brazil has already taken a much slower approach than some of its neighbors, including Ecuador and Peru who regulated in similar ways as Colombia right before the pandemic. Despite being the first ones to open the door to medical cannabis and benefit from the influx of foreign investment dollars, their local producers did not win the race.
Compassionate use, despite heavy bureaucratic load that may affect patient wellbeing and the local healthcare system, is, nonetheless, a first step towards legalizing medical cannabis. This decision also allowed Brazil to create a stable patient base that will both benefit and purchase locally produced flowers and extracts.
In the next phase, a question of quantity vs. quality has proven to be a crucial part of the race. While Colombians requested licenses that ended up being unused by many, the remaining players focused on quality and can now compete in the international market. At the end, the race turned out to be towards achieving European standards to supply the German market instead of being the first to request licenses.
As Brazil begins the journey of issuing specific regulations for local production, the goal of reaching outstanding quality to heal several patient needs should be constantly reminded instead of rushing into a licensing framework that may result in more questions than answers.
Lesson #2: Social Equity is a Privilege Earned, not a Promise Guaranteed.
Colombian regulators wanted to ensure small producers could compete in the newly regulated medical cannabis market, and it became a constant concern amongst the government at the time. Eventually, the Ministry of Justice issued Decree 613 in 2018 in which all THC licensed producers were required to purchase 10% of their THC quota from small and medium-sized producers.
Although on paper it seemed like a reasonable concession, troubles quickly surfaced because that isolated requirement was simply not enough. Small and medium sized producers did not have access to the capital or infrastructure to produce medical cannabis the quality larger producers required. A requirement of providing technical assistance was introduced in 2021, but it was still insufficient in a country where rural areas have long struggled against violence and isolation.
Brazilian authorities have begun to shape this path towards social equity and justice within the cannabis space as noted in RDC No. 1,014/2026 by allowing non-profit patient associations to access cultivation licenses. However, such efforts can only be materialized by issuing realistic frameworks that ensure such non-profit associations and any other benefited parties have the tools to participate in the market.
Regulations aiming to strengthen local communities, reinvesting in their own development and providing the knowledge and tools to compete against commercial producers are a first step towards building sustainable social equity measures in one of the world’s most unequal regions.
Lesson #3: Unanswered Questions Leave Room for Unnecessary Speculation
A large number of industries can use non-psychoactive cannabis, or hemp as defined by the 2018 Farm Bill, but their regulations have proven to be largely challenging. Aside from the medical and pharmaceutical uses of cannabis, food, beverages, vitamins, cosmetics and tailored formulations prepared on a per-patient basis each have unique characteristics that must be properly regulated to ensure consumer safety.
In the Colombian market, after issuing more than 1,000 cultivation licenses, the government found itself caught up in confusion on how to determine standards of safety. In the meantime, licensed producers were demanding regulations to begin commercial operations and stop relying on raising capital, so regulatory agencies were feeling the pressure.
Instead of focusing on single product categories and regulating one by one, the government opened several discussions at once ranging from vitamins to beverages and everything in between. The result was not an increase in cash-flow and sales, but rather an unmatched level of uncertainty with unclear regulations.
Brazil is right on time to focus on one category at a time and avoid the temptation of allowing for markets that may be more complex. Starting with local production to meet specific patient needs may lead to further discussions on the food and beverages space instead of addressing both regulations at once.
Final Thoughts
Regulating medical cannabis has proven to be immensely challenging. However, offering patients suffering diverse pathologies therapeutic solutions depends on local production regulations. Thus, developing a framework that allows for the sustainable production of high-quality medical cannabis is the best way to serve the local ecosystem and prioritizing patients.
Brazil is going through a unique time in which the window to move from an imports-only cannabis economy into local production is still open and can offer unique opportunities for local companies and communities to power the local economy.
To make sure the opportunity reaches its full potential, a patient, considerate and precise approach can make ANVISA an example of how to regulate medical cannabis in a region where agricultural potential can make a real difference for patients both inside and outside Latin America.

